Source comparison
PT-141 Erectile Dysfunction Research Mechanism: Clinical Comparison
PT-141 MC3R/MC4R receptors in hypothalamus. Central arousal 30–60 minutes 6–8 hours Moderate. Bypasses endothelial damage entirely High. Directly addresses central inhibition Nausea in 18–40%, transient BP elevation Sildenafil (Viagra) PDE5 inhibition in corpu
This comparison does not assign a generated winner or score.
- PT-141
- MC3R/MC4R receptors in hypothalamus. Central arousal
- 30–60 minutes
- 6–8 hours
- Moderate. Bypasses endothelial damage entirely
- High. Directly addresses central inhibition
- Nausea in 18–40%, transient BP elevation
- Sildenafil (Viagra)
- PDE5 inhibition in corpus cavernosum. Peripheral vasodilation
- 4–6 hours
- High. Requires intact NO signalling
- Moderate. Relies on baseline arousal
- Requires sexual stimulation to activate
- Tadalafil (Cialis)
- PDE5 inhibition. Long-acting peripheral vasodilation
- 30–120 minutes
- 24–36 hours
- High. Daily dosing maintains readiness
- Moderate. Mechanical support only
- Minimal effect on desire or arousal
- Alprostadil (Caverject)
- Direct prostaglandin E1 smooth muscle relaxation
- 5–10 minutes
- Very High. Bypasses all upstream pathways
- Low. No central arousal component
- Requires intracavernosal injection
- Professional Assessment
- PT-141 represents the only FDA-studied treatment targeting central arousal mechanisms. Ideal for patients with intact vasculature but impaired desire, or those unresponsive to PDE5 inhibitors due to nerve damage or medication interactions.